Gastroenterology

Brian Feagan shares the SELECTION study findings showing a role for filgotinib in the treatment of biologic-naive and experienced patients with moderately to severely active ulcerative colitis (10:21).

Silvio Danese discusses the STARDUST trial looking at the benefits of a treat-to-target strategy for optimising ustekinumab treatment in Crohn’s disease based on endoscopic and clinical outcomes (3:28).

Silvio Danese outlines the 52-week TRUE NORTH study findings showing the benefits of ozanimod in patients with moderate-to-severe ulcerative colitis (4:11).

Ryan Ungaro reports results from the updated SECURE-IBD registry looking at the impact patient characteristics and immunosuppressants have on COVID-19 outcomes in patients with IBD (5:45).

Peter Bossuyt discusses his pragmatic trial looking at the potential of ultraproactive therapeutic drug monitoring to improve infliximab dosing in patients with inflammatory bowel disease (5:38).